The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults

Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2009, Pages 219-228

  Nichols, Alice I ^a   Fatato, Penny ^a   Shenouda, Magdy ^b   Paul, Jeffrey ^a   Isler, Jennifer A ^a   Pedersen, Ronald D ^a   Jiang, Qin ^a   Ahmed, Saeeduddin ^a   Patroneva, Albena ^a  

^a PFIZER INC   (United States)

^b MDS Inc   (Canada)

Author keywords

Antidepressant; Cytochrome P450 2D6; Desipramine; Desvenlafaxine; Drug drug interaction; Paroxetine

Indexed keywords

CYTOCHROME P450 2D6; DESIPRAMINE; DESVENLAFAXINE; DRUG METABOLITE; HYDROXYDESIPRAMINE; PAROXETINE; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ETHNICITY; FEMALE; GENOTYPE; HEADACHE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DESIPRAMINE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PAROXETINE; UNITED STATES; YOUNG ADULT;

EID: 58849100808     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008326716     Document Type: Article

References (21)

1. Zanger UM, Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 23-37.
2. Evans WE, Relling MV Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 ; 286: 487-491.
3. Eichelbaum M., Spannbrucker N., Steincke B., Dengler HJ Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 ; 16: 183-187.
4. Mahgoub A., Idle JR, Dring LG, Lancaster R., Smith RL Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977 ; 2: 584-586.
5. Kirchheiner J., Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 ; 1770: 489-494.
6. Amchin J., Ereshefsky L., Zarycranski W., Taylor K., Albano D., Klockowski PM Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol. 2001 ; 41: 443-451.
7. Preskorn SH Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part I). J Psychiatr Pract. 2003 ; 9: 150-158.
8. Preskorn SH, Greenblatt DJ, Flockhart D., et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol. 2007 ; 27: 28-34.
9. Shin JG, Soukhova N., Flockhart DA Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 ; 27: 1078-1084.
10. Silkey B., Preskorn SH, Golbeck A., et al. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract. 2005 ; 11: 16-26.
11. Sallee FR, Pollock BG Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet. 1990 ; 18: 346-364.
12. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 ; 60: 284-295.
13. Daly AK Pharmacogenetics of the cytochromes P450. Curr Top Med Chem. 2004 ; 4: 1733-1744.
14. Isler JA, Vesterqvist OE, Burczynski ME Analytical validation of genotyping assays in the biomarker laboratory. Pharmacoge- nomics. 2007 ; 8: 353-368.
15. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals ; 2008.
16. Otton SV, Ball SE, Cheung SW, Inaba T., Rudolph RL, Sellers EM Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996 ; 41: 149-156.
17. Owen JR, Nemeroff CB New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998 ; 7 (suppl 1). 24-32.
18. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research, US Department of Health and Human Services ; 2006.
19. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 ; 101: 113-121.
20. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004 ; 25: 193-200.
21. de Leon J., Susce MT, Pan RM, Fairchild M., Koch WH, Wedlund PJ The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005 ; 66: 15-27.